Skip to main content

Table 2 Details of NSAIDs/low-dose aspirin

From: Non-steroidal anti-inflammatory drug-induced enteropathy as a major risk factor for small bowel bleeding: a retrospective study

  N = 37 (100%)
(NSAID = 17/Low-dose aspirin = 21)a
Indication
 Coronary artery disease 11 (29.7)
 Other cardiovascular disease 9 (24.3)
 Musculoskeletal disease 15 (40.5)
 Unknown 3 (8.1)
Duration
  < 1 month 2 (5.4)
 1–6 months 11 (29.7)
  > 6 months 22 (59.5)
 Unknown 2 (5.4)
Concurrent medication
 Clopidogrel 6 (16.2)
 Warfarin/NOAC 7 (18.9)
 Other anti-platelet agent 3 (8.1)
 None 21 (56.8)
Site of bleeding
 Small bowel 33 (89.2)
 Stomach 2 (5.4)
 Undetermined 2 (5.4)
Etiology of small bowel bleedingb
 NSAID-induced enteropathy 25 (75.8)
 Angioectasia 7 (21.2)
 Others 1 (3.0)
Initial management of NSAID-induced enteropathyc
 Discontinue NSAID/low-dose aspirin 20 (80.0)
 Continue NSAID/low-dose aspirin 2 (8.0)
+ Mucosal protective agentd
 Unknown 3 (12.0)
  1. a One patient had a history of both NSAID and low dose aspirin
  2. b The denominator is 33 patients with confirmed small bowel bleeding on capsule endoscopy
  3. c The denominator is 25 patients with small bowel bleeding associated with NSAID/low-dose aspirin
  4. d Mucosal protective agent indicates rebamipide, sucralfate, or sodium alginate
  5. NSAID, nonsteroidal anti-inflammatory drug; NOAC, non-vitamin K antagonist oral anticoagulant